Afmd stock price target

Get today's Affimed NV stock price and latest AFMD news as well as Affimed is an additional CD16A NK-cell TandAb targeting a validated solid tumor target,  All important share information about Affimed N.V. : Investment Calculator, Historical Price, Share Information and Share Series.

AFMD Price Target | Affimed Stock Forecast & Ratings See Affimed price target based on analysts offering 12 month price targets for Affimed in the last 3 months. Follow AFMD to track price target and stock forecast updates from top wall street analysts. AFMD Price Target and Analyst Ratings (Affimed) | MarketBeat Nov 05, 2019 · 1 Wall Street analysts have issued ratings and price targets for Affimed in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 509.76%. The high price target for AFMD is $10.00 and the low price target for AFMD is $10.00.

AFMD - Affimed N.V. Stock Price - Barchart.com

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system AFMD Stock Price & Charts | Affimed In depth view into AFMD (Affimed) stock including the latest price, news, dividend history, earnings information and financials. AMD: 2019 Target Prices (NASDAQ:AMD) | Seeking Alpha Using 2019 financials, AMD target prices will be $20, $21.7, $22, $23, and $26 which corresponds to the current time, 2018 Q4, 2019 Q1, 2019 Q2, and 2019 Q3, respectively. The Street target price

Get breaking news and analysis on Affimed N.V. (AFMD) stock, price quote and chart, trading and investing tools. Get breaking news and analysis on Affimed N.V. (AFMD) stock, price quote and chart

AFMD Stock Quote - Affimed N.V. Price - Nasdaq Stock quote for Affimed N.V. Common Stock (AFMD) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. AFMD Affimed Therapeutics — Stock Price and Discussion ... Apr 03, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.

Sep 27, 2019 · Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma.

Sep 27, 2019 · Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. AFMD: Affimed NV - Stock Price, Quote and News - CNBC Get Affimed NV (AFMD:NASDAQ) real-time stock quotes, news and financial information from CNBC. Killer Stocks to Buy That No One Knows About: Affimed N.V ... That day the SunTrust set price target on the stock to $7. Leerink Partners was of a view that AFMD is Mkt Perform in its latest report on May 19, 2016. Laidlaw thinks that AFMD is worth Buy rating. This was contained in the firm’s report on December 10, 2015 in which the stock’s price target … Affimed N.V. (AFMD) stock price, quote, history & news ... Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates. Affimed N.V. (AFMD) delivered earnings and revenue surprises of -35.71% and -65.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Affimed NV Stock Quote: AFMD Stock News, Quotes, Analysis ...

Click to view NMQ:AFMD's StockReport. StockRank™ AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR- wild  Dell Technologies price target lowered to $39 from $55 at Raymond James » 08: 08. 04/06/20 (DELL) to $39 from $55 and keeps an Outperform rating on the shares. AFMD. Affimed N.V.. $1.60 /. +0.02 (+1.27%). , RHHBY. Roche. $0.00 /. NASDAQ:AFMD / Affimed N.V. - Short Interest, Short Volume, Short Squeeze short interest buy buying actual shares, which in turn drives the price up even  Split History. Stock splits are used by Affimed N.V. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets   26 Mar 2020 That day the ROTH Capital set price target on the stock to $1.20. A look at its technical shows that AFMD's 50-day SMA is 2.4083 while its  AFMD Price Target | Affimed Stock Forecast & Ratings See Affimed price target based on analysts offering 12 month price targets for Affimed in the last 3 months. Follow AFMD to track price target and stock forecast updates from top wall street analysts.

5 days ago · AFMD stock construct a change of 0.63 in a total of its share price and finished its trading at 1.59. Affimed N.V. institutional ownership is held at 58.80% while insider ownership was 7.50%. As of now, AFMD has a P/S, P/E and P/B values of 2.75, 0.00 and 4.08 respectively. Its P/Cash is valued at 1.45. AFMD Stock Price and Chart — NASDAQ:AFMD — TradingView — UK TradingView UK. View live AFFIMED N V chart to track its stock's price action. Find market predictions, AFMD financials and market news. $AFMD Stock Technical Analysis | Affimed | SwingTradeBot.com Sep 27, 2019 · Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. AFMD: Affimed NV - Stock Price, Quote and News - CNBC